We report 3 patients with nephrotic syndrome ascribed to primary systemic AL amyloidosis that were successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone. M-protein in serum disappeared soon after VAD, and nephrotic syndrome gradually improved in parallel with a decrease in daily protein excretion in urine. Long-term follow-up of these patients showed neither relapse of nephrotic syndrome nor reappearance of M-protein. High-dose melphalan followed by autologous stem cell support is a standard therapy for primary systemic AL amyloidosis, but in high-risk cases for this treatment, such as elderly patients and those with multiple organ involvement, VAD might be a therapeutic option.

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.47.0709DOI Listing

Publication Analysis

Top Keywords

nephrotic syndrome
16
primary systemic
12
systemic amyloidosis
12
amyloidosis treated
8
treated vad
8
vad vincristine
8
vincristine doxorubicin
8
doxorubicin dexamethasone
8
nephrotic
4
syndrome primary
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!